Indivior (INDV) Rating Reiterated by Morgan Stanley

Indivior (LON:INDV)‘s stock had its “equal weight” rating restated by stock analysts at Morgan Stanley in a research report issued on Friday. They presently have a GBX 410 ($5.49) price target on the specialty pharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential upside of 1.38% from the company’s current price.

INDV has been the topic of a number of other research reports. Jefferies Group upped their price target on shares of Indivior from GBX 490 ($6.56) to GBX 540 ($7.23) and gave the company a “buy” rating in a research note on Friday, August 11th. Numis Securities reaffirmed a “buy” rating and set a GBX 640 ($8.57) price target on shares of Indivior in a report on Thursday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 470 ($6.29) price target on shares of Indivior in a report on Thursday, August 3rd. Citigroup reaffirmed a “neutral” rating and set a GBX 280 ($3.75) price target on shares of Indivior in a report on Thursday, October 26th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 400 ($5.36) price target on shares of Indivior in a report on Friday, September 15th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of GBX 468.14 ($6.27).

Shares of Indivior (INDV) opened at GBX 404.40 ($5.42) on Friday. Indivior has a 52-week low of GBX 246.50 ($3.30) and a 52-week high of GBX 421.50 ($5.64).

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/01/indivior-indv-rating-reiterated-by-morgan-stanley.html.

About Indivior

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply